BioWorld

May 9, 2002

View Archived Issues

Amgen Paying Roche $137.5M For European Neupogen Rights

Amgen Inc. said it will pay Roche Holding AG $137.5 million to gain control over European assets and business related to two white-cell boosters that are sold in the U.S. under the names Neupogen and Neulasta. (BioWorld Today) Read More

GenStar, Applied Molecular Sign Collaborations With Centocor

Read More

Striatal Genes, Proteins Couple, Uncouple As Mutant Huntingtin Gene Interferes With Brain Cells

Read More

Affinium, Pfizer Enter Potential $30M Drug Discovery Alliance

Read More

Other News To Note

Read More

Immusol, Vertex Collaborating To Discover Protein Targets

Read More

U.S. Patent Disclosures

Read More